# Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

> **NCT05734040** · PHASE2 · COMPLETED · sponsor: **Osivax** · enrollment: 478 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** OVX836 480µg
- **BIOLOGICAL:** Fluarix Tetra
- **BIOLOGICAL:** Afluria Quad
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05734040
- **Lead sponsor:** Osivax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2023-08-10
- **Final completion:** 2024-01-15
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05734040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05734040, "Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05734040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*